Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01325493 · ClinicalTrials.gov registry record · Phase 4

Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia

A Phase 4 study, sponsored by Julia Finkel.

Completed
Registry status
Phase 4
Development phase
54
Enrollment target

NCT01325493: Completed Phase 4 study, sponsored by Julia Finkel.

NCT01325493 is a Phase 4 study that has completed, run by Julia Finkel. The registered enrollment target is 54 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01325493, a Phase 4 study, has completed, sponsored by Julia Finkel.

COMPLETED
Registry status
Phase 4
Development phase
54 participants
Enrollment target

Study Summary

The purpose of this study is to: 1\. Establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years, undergoing posterior spinal fusion and instrumentation.

Primary Outcome

Morphine consumption (mg/kg) was measured over time in the Ketamine group and compared to the Control (saline) group. Values are for each 24 hour time period and displayed as hours post surgery.

Interventions

  • DRUG Ketamine
  • DRUG Normal Saline

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2010-01
Est. Completion 2012-09
Phase Phase 4
Julia Finkel

7 total trials

What the finished NCT01325493 record still lists

NCT01325493 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.

NCT01325493 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01325493 about?

NCT01325493 is a clinical study titled "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia". The purpose of this study is to: 1\. Establish whether ketamine can decrease opioid consumption and modulate the onset of opioid tolerance and prevent opioid-induced hyperalgesia in pediatric subjects, ages 10 years to 18 years, undergoing posterior spinal fusion and instrumentation.

What is the current status of trial NCT01325493?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2010-01. Estimated completion is 2012-09.

What interventions are being tested in trial NCT01325493?

The interventions under investigation include: Ketamine (DRUG), Normal Saline (DRUG).

Who is sponsoring clinical trial NCT01325493?

This trial is sponsored by Julia Finkel, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01325493's enrollment target sits among peer trials

54 1223rd of 2000 higher than 772 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01325493, the US trial registry maintained by the National Library of Medicine. NCT01325493 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.